242 related articles for article (PubMed ID: 35768005)
21. Re: The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer.
Huang M; Guo J
Clin Imaging; 2023 Jan; 93():115-116. PubMed ID: 35989110
[TBL] [Abstract][Full Text] [Related]
22. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Bracci S; Dolciami M; Trobiani C; Izzo A; Pernazza A; D'Amati G; Manganaro L; Ricci P
Radiol Med; 2021 Nov; 126(11):1425-1433. PubMed ID: 34373989
[TBL] [Abstract][Full Text] [Related]
23. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
Li J; Ge S; Sang S; Hu C; Deng S
Front Oncol; 2021; 11():789014. PubMed ID: 34976829
[TBL] [Abstract][Full Text] [Related]
26. The radiomic biomarker in non-small cell lung cancer:
Wang YB; He X; Song X; Li M; Zhu D; Zhang F; Chen Q; Lu Y; Wang Y
Clin Radiol; 2023 Oct; 78(10):e732-e740. PubMed ID: 37419772
[TBL] [Abstract][Full Text] [Related]
27. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
28. The Usefulness of Machine Learning-Based Evaluation of Clinical and Pretreatment [
Nakajo M; Kawaji K; Nagano H; Jinguji M; Mukai A; Kawabata H; Tani A; Hirahara D; Yamashita M; Yoshiura T
Mol Imaging Biol; 2023 Apr; 25(2):303-313. PubMed ID: 35864282
[TBL] [Abstract][Full Text] [Related]
29. Predicting programmed death-ligand 1 expression level in non-small cell lung cancer using a combination of peritumoral and intratumoral radiomic features on computed tomography.
Shiinoki T; Fujimoto K; Kawazoe Y; Yuasa Y; Kajima M; Manabe Y; Ono T; Hirano T; Matsunaga K; Tanaka H
Biomed Phys Eng Express; 2022 Feb; 8(2):. PubMed ID: 35051908
[TBL] [Abstract][Full Text] [Related]
30. Application of 18 F-fluorodeoxyglucose PET/CT radiomic features and machine learning to predict early recurrence of non-small cell lung cancer after curative-intent therapy.
Park SB; Kim KU; Park YW; Hwang JH; Lim CH
Nucl Med Commun; 2023 Feb; 44(2):161-168. PubMed ID: 36458424
[TBL] [Abstract][Full Text] [Related]
31. Application of 18F-FDG PET/CT imaging radiomics in the differential diagnosis of single-nodule pulmonary metastases and second primary lung cancer in patients with colorectal cancer.
Yu Y; Zhu J; Sang S; Yang Y; Zhang B; Deng S
J Cancer Res Ther; 2024 Apr; 20(2):599-607. PubMed ID: 38687930
[TBL] [Abstract][Full Text] [Related]
32. Machine learning based on clinico-biological features integrated
Ren C; Zhang J; Qi M; Zhang J; Zhang Y; Song S; Sun Y; Cheng J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1538-1549. PubMed ID: 33057772
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
34. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
[TBL] [Abstract][Full Text] [Related]
35. Value of
Hu Y; Zhao X; Zhang J; Han J; Dai M
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):231-240. PubMed ID: 32588088
[TBL] [Abstract][Full Text] [Related]
36. IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER.
Agüloğlu N; Aksu A; Akyol M; Katgı N; Doksöz TÇ
Nuklearmedizin; 2022 Dec; 61(6):433-439. PubMed ID: 35977671
[TBL] [Abstract][Full Text] [Related]
37. Graph Neural Network Model for Prediction of Non-Small Cell Lung Cancer Lymph Node Metastasis Using Protein-Protein Interaction Network and
Ju H; Kim K; Kim BI; Woo SK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255770
[TBL] [Abstract][Full Text] [Related]
38. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
39. Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR.
Vuong D; Tanadini-Lang S; Huellner MW; Veit-Haibach P; Unkelbach J; Andratschke N; Kraft J; Guckenberger M; Bogowicz M
Med Phys; 2019 Apr; 46(4):1677-1685. PubMed ID: 30714158
[TBL] [Abstract][Full Text] [Related]
40. Tumor metabolic volume by
Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Shiono A; Miura Y; Murayama Y; Kobayashi K; Kagamu H; Kuji I
Sci Rep; 2020 Sep; 10(1):14990. PubMed ID: 32929123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
